touchONCOLOGY spoke to Ken Kato (Tokyo, Japan) to discuss his presentation on the JCOG1109 NExT study, a randomized controlled phase III trial comparing two chemotherapy regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally advanced esophageal cancer.
Questions
- Â Â Â What are the limitations of cisplatin plus 5-fluorouracil neoadjuvant treatment as the standard of care for locally advanced esophageal squamous cell cancer? (00:21-01:33)
- Â Â Â What were the aims and design of the JCOG1109 NExT clinical trial? (01:33-04:15)
- Â Â Â What were the primary and secondary efficacy endpoints and how well were they achieved? (04:15-05:00)
- Â Â Â What was the safety profile of the triplet chemotherapy regimen? (05:00-07:40)
- Â Â Â What will be the likely impact of these findings on clinical practice? (07:42-10:22)
Speaker Disclosure: Ken Kato has no conflicts of interest to declare in relation to this video.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Sophie Nickelson.
Filmed in coverage of the ASCO Gastrointestinal Cancers Symposium 2022.
